NovaMedica is in advanced negotiations to secure Russia and CIS rights for a wide range of innovative Products. We are seeking specialty pharmaceutical drugs and devices from various potential US and European partners (including Domain Associates, Inc. portfolio companies) spanning several high-growth therapeutic areas in hospital inpatient, hospital outpatient and specialty care clinical contexts. Products can be both FDA/EMA approved and phase 2B/3 late-stage development. Please check back regularly as we grow our pipeline to serve this exciting market.
EMA’s new guide to implementing IDMP data standards triggers the countdown to change
04 March 2021
04 March 2021
COVID-19 Vaccine Makers Overcome Challenges to Ramp Up Production
03 March 2021
FDA greenlights home COVID-19 testing kits from Quidel, Eurofins
03 March 2021